24th Feb 2014 13:18
(In an item published February 21 at 1502 GMT, the technology was described incorrectly. The correct version follows.)
LONDON (Alliance News) - Skyepharma PLC Friday reminded investors that its inhalation formulation technology will be used in GlaxoSmithKline's chronic obstructive pulmonary disease treatment Anoro.
Skyepharma will be entitled to low single-digit royalty on net sales of products using the licensed technology, capped at a maximum amount of GBP3 million per year.
Skyepharma said it could see a potential income of up to GBP9 million from Glaxo's combination products Anoro and Breo, also for the treatment of COPD, as well as Glaxo's monotherapy Incruse.
Glaxo received recommendation for marketing authorisation from the European Medicines Agency's committee for Medical Products for Human Use for Anoro and Incruse on Thursday and Friday respectively.
Shares in Skyepharma were trading up 6.0% at 195.00 pence Friday afternoon.
By Hana Stewart-Smith; [email protected]; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L